Tanvex BioPharma News and Resources

Tanvex BioPharma, Inc. has announced the completion of its acquisition of Bora Biologics Co., Ltd., a subsidiary of Bora Pharmaceuticals. The combined entity’s CDMO services will operate under the Bora Biologics name while continuing to be owned by Tanvex. “The

Tanvex BioPharma Inc., a biosimilar-focused biopharmaceutical company and CDMO, has announced the appointment of Stephen Lam as its new Chief Executive Officer, effective September 5, 2024. Lam succeeds Henry Chen, who will remain the company’s Chairman until the completion of